{"id":"W2084920067","doi":"10.1097/01.jto.0000284067.45483.01","title":"P3-091: A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"Boehringer Ingelheim (Canada); Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Tolerability; Regimen; Lung cancer; Oncology; Internal medicine; Pharmacology; Combination therapy; Chemotherapy; Adverse effect; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001102926,0.00142554,0.00268264,0.000446892,0.000535491,0.001167993,0.001224824,0.001314383,0.004422076],"category_scores_gemma":[0.0007229677,0.000743293,0.001528953,0.0005502814,0.001304305,0.001162617,0.0004229131,0.005402745,0.001214282],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009717215,"about_ca_system_score_gemma":0.001857413,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002926039,"about_ca_topic_score_gemma":0.006072509,"domain_scores_codex":[0.9996593,0.0001164768,0.00001327123,0.00006809337,0.00002940332,0.0001134917],"domain_scores_gemma":[0.9994273,0.00008883326,0.00006033577,0.00004133069,0.00002142315,0.0003607852],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6249355,0.1084852,0.005531085,0.00110254,0.002381138,0.0005020053,0.0004020133,0.002942025,0.05873074,0.0005354246,0.008384828,0.1860675],"study_design_scores_gemma":[0.5575246,0.4223095,0.01165501,0.00003142045,0.0005796152,0.0003889215,0.0000919883,0.001383638,0.00343072,0.0002094419,0.00235001,0.00004511132],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921247,0.001965766,0.0005266368,0.0006660977,0.0002073927,0.001229182,0.001177987,0.0001780992,0.001924053],"genre_scores_gemma":[0.9884841,0.002447753,0.001444877,0.0007541491,0.0001819883,0.001509242,0.002237157,0.00006020324,0.0028806],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004422076,"threshold_uncertainty_score":0.01479328,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01389177490867105,"score_gpt":0.3921952427329768,"score_spread":0.3783034678243058,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}